HAVCR2 and cancer: To validate this new technology, we set out to generate antibodies with high binding affinity for T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3), which is a promising candidate for cancer immunotherapy [25, 26] that was first reported in 2002 [27].